Seção de Ensino

URI Permanente desta comunidade

https://dspace.inc.saude.gov.br/handle/123456789/14

Navegar

Navegando Seção de Ensino por Autor "Abubakar, Ibrahim"

Agora exibindo 1 - 1 de 1
  • Item
    Previous BCG vaccination is associated with less severe clinical progression of COVID-19
    (BMC Medicine, 2023) Pereira, Susan Martins; Barreto, Florisneide Rodrigues; Souza, Ramon Andrade de; Santos, Carlos Antonio de Souza Teles; Pereira, Marcos; Paixão, Enny Santos da; Lima, Carla Cristina Oliveira de Jesus; Natividade, Marcio Santos da; Lindoso, Ana Angélica Bulcão Portela; Fernandes, Eder Gatti; Junior, Evonio Barros Campelo; Pescarini, Julia Moreira; Andrade, Kaio Vinicius Freitas de; Souza, Fernanda Mattos de; Britto, Elisangela Alves de; Nunes, Ceuci; Ichihara, Maria Yuri; Dalcolmo, Margareth; Trajman, Anete; Barral‐Netto, Manoel; Abubakar, Ibrahim; Barreto, Mauricio Lima; Ximenes, Ricardo Arraes de Alencar; Rodrigues, Laura Cunha
    Background BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is associated with less severe clinical progression of COVID-19 Methods A case-control study comparing the proportion with a BCG vaccine scar (indicating previous vaccination) in cases and controls presenting with COVID-19 to health units in Brazil. Cases were subjects with severe COVID-19 (O2 saturation < 90%, severe respiratory efort, severe pneumonia, severe acute respiratory syndrome, sepsis, and sep‐ tic shock). Controls had COVID-19 not meeting the defnition of “severe” above. Unconditional regression was used to estimate vaccine protection against clinical progression to severe disease, with strict control for age, comorbidity, sex, educational level, race/colour, and municipality. Internal matching and conditional regression were used for sensitivity analysis. Results BCG was associated with high protection against COVID-19 clinical progression, over 87% (95% CI 74–93%) in subjects aged 60 or less and 35% (95% CI −44–71%) in older subjects. Conclusions This protection may be relevant for public health in settings where COVID-19 vaccine coverage is still low and may have implications for research to identify vaccine candidates for COVID-19 that are broadly protec‐ tive against mortality from future variants. Further research into the immunomodulatory efects of BCG may inform COVID-19 therapeutic research.